LONDON – The competitive potential of Alpharadin in treating bone metastases in patients with hormone-resistant prostate cancer was underlined in the first formal presentation of the Phase III study ...

OSLO, August 28 /PRNewswire-FirstCall/ --Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of ...

Research was presented at the ASCO Genitourinary Cancers Symposium, including advancements in prostate cancer. The American Society of Clinical Oncology (ASCO) hosted the annual Genitourinary Cancers ...

Tulane Cancer Center (TCC) is seeking patients to participate in a clinical trial of a new drug to treat late-stage prostate cancer. TCC is the first location in the United States to take part in this ...

CHICAGO—Alpharadin, an investigational agent, may relieve pain and improve survival in men with metastatic castration-resistant prostate cancer (CRPC), according to data presented at the American ...

After receiving a diagnosis of prostate cancer, a man will need to decide how aggressively to treat the cancer, weighing the severity of the disease against the risk of side effects. Since early ...

PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP). Neoadjuvant ...

May 21, 2012 (Atlanta, Georgia) — In patients with bone metastases and castration-resistant prostate cancer (CRPC), radium-223 chloride (Ra-223) significantly prolonged overall survival and delayed ...

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate ...

With regulatory filings for its prostate cancer therapy, Alpharadin (radium-223 chloride), expected in mid-2012, Algeta ASA is seeking up to NOK260 million (US$45.4 million) in a private placement to ...